Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription 27.10.2025 1 BJU Int 3 BMC Cancer 1 Cancer 1 Cancer Lett 1 Cancer Res 3 Eur Urol 1 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 1 J Nucl Med 1 Lancet Oncol 1 N Engl J Med 1 Proc Natl Acad Sci U S A 2 Prostate 1 Ther Adv Urol 4 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. MA L, Lu R, Dong Z
   Comment on 'Renal, bladder and prostate cancer surgery outcomes with respect to team familiarity'.
   BJU Int. 2025 Oct 23. doi: 10.1111/bju.70032.
   PubMed        
   
   

   
   BMC Cancer

2. ESMAELI M, Dehghanpour Dehabadi M
   Curcumin in prostate cancer: a systematic review of molecular mechanisms and nanoformulated therapeutic strategies.
   BMC Cancer. 2025;25:1609.
   PubMed         Abstract available
   
   
3. MAROTO JP, Puente J, Conde Moreno A, Juarez A, et al
   Real-world evidence in localized and locally advanced prostate cancer: applying artificial intelligence to electronic health records.
   BMC Cancer. 2025;25:1618.
   PubMed         Abstract available
   
   
4. CHEN H, Chen J, Lyu F, Ma M, et al
   Comparison of the safety and efficacy of moderately hypofractionated and conventionally fractionated radiotherapy for localized prostate cancer: evidence from 9074 men in 13 randomized clinical trials.
   BMC Cancer. 2025;25:1634.
   PubMed         Abstract available
   
   

   
   Cancer

5. GOGEBAKAN KC, Elsisi Z, Montano-Campos F, Owens L, et al
   Prostate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long-term survival.
   Cancer. 2025;131:e70131.
   PubMed         Abstract available
   
   

   
   Cancer Lett

6. NIKHIL K, Kamra M, Raza A, Shah K, et al
   Corrigendum to "Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo" [Cancer Lett. 498 (2021) 1-18].
   Cancer Lett. 2025 Oct 17:218044. doi: 10.1016/j.canlet.2025.218044.
   PubMed        
   
   

   
   Cancer Res

7. NASR MM, Wadie B, Li T, Frieling JS, et al
   PRDM16 Regulates Prostate Cancer Cell Dormancy and Prevents Bone Metastatic Outgrowth.
   Cancer Res. 2025 Oct 17. doi: 10.1158/0008-5472.CAN-24-4809.
   PubMed         Abstract available
   
   

   
   Eur Urol

8. FREEDLAND SJ, Shore N
   Reply to Xianghu Meng, Yibo Hua, and Rijin Song's Letter to the Editor re: Stephen J. Freedland, John P. Mulhall, Martin Gleave, et al. Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc
   Eur Urol. 2025 Oct 22:S0302-2838(25)04744-X. doi: 10.1016/j.eururo.2025.09.4179.
   PubMed        
   
   
9. SCHELTEMA MJV, Stricker PD
   Prospective Multicentre Validation of Focal Irreversible Electroporation as an Attractive Treatment Option for Localised Intermediate-risk Prostate Cancer.
   Eur Urol. 2025 Oct 16:S0302-2838(25)04738-4. doi: 10.1016/j.eururo.2025.
   PubMed        
   
   
10. VIGNESWARAN HT, Palsdottir T, Micoli C, Tilki D, et al
    Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial.
    Eur Urol. 2025 Oct 16:S0302-2838(25)04735-9. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    

    
    Int J Cancer

11. TANG Y, Han Z, Yi X, Li J, et al
    Survival improvements and disparities in metastatic prostate adenocarcinoma, clear cell renal cell carcinoma, and urothelial carcinoma of bladder.
    Int J Cancer. 2025;157:2485-2494.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

12. WIERSMA RG, de Vries KC, Heemsbergen WD, de Hoop EO, et al
    Hypofractionated Dose Escalation versus Conventionally Fractionated Radiotherapy for Patients with Intermediate- and High-risk Localized Prostate Cancer: Long-term Results of the HYPRO trial.
    Int J Radiat Oncol Biol Phys. 2025 Oct 15:S0360-3016(25)06340.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

13. EINSTEIN DJ, Abel ML, Aragon-Ching JB, Arlen PM, et al
    National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
    J Clin Oncol. 2025 Oct 23:JCO2501693. doi: 10.1200/JCO-25-01693.
    PubMed         Abstract available
    
    

    
    J Nucl Med

14. RAHBAR K, Giesel FL, Herrmann K, Yun M, et al
    Efficacy of [(18)F]PSMA-1007 PET/CT in Primary Staging of Prostate Carcinoma: A Systematic Review and Metaanalysis.
    J Nucl Med. 2025 Oct 23:jnumed.125.269818. doi: 10.2967/jnumed.125.269818.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

15. KOSTOS L, Buteau JP, Xie J, Cardin A, et al
    Lutetium-177 [(177)Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.
    Lancet Oncol. 2025 Oct 18:S1470-2045(25)00559.
    PubMed         Abstract available
    
    

    
    N Engl J Med

16. SHORE ND, Luz MA, De Giorgi U, Gleave M, et al
    Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2025 Oct 19. doi: 10.1056/NEJMoa2510310.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

17. YUAN S, Ming DJ, He J, Liu MY, et al
    A PHF19-YTHDC1 condensate switches EZH2-mediated gene suppression to activation for prostate cancer progression.
    Proc Natl Acad Sci U S A. 2025;122:e2510386122.
    PubMed         Abstract available
    
    

    
    Prostate

18. KAWAI T, Maki K, Taguchi S, Fujii Y, et al
    Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration-Resistant Prostate Cancer.
    Prostate. 2025 Oct 21. doi: 10.1002/pros.70082.
    PubMed         Abstract available
    
    
19. KIDD M, Rempega G, Kepinski M, Slomian S, et al
    Utility of the PROSTest, a Novel Blood-Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease.
    Prostate. 2025 Oct 23. doi: 10.1002/pros.70086.
    PubMed         Abstract available
    
    

    
    Ther Adv Urol

20. LEBRET T, Crehange G, Pello-Leprince-Ringuet N, Perrot V, et al
    Treatment of aggressive prostate cancer with triptorelin in real life in France: the TALISMAN study.
    Ther Adv Urol. 2025;17:17562872251382970.
    PubMed         Abstract available
    
    

    
    Urology

21. KHAN S, Harper A, Yang L, Sutcliffe S, et al
    Reply to Letter to the Editor on "Impact of Age, Marital Status, Smoking, and Alcohol Consumption on Urinary and Sexual Function in Prostate Cancer Patients Treated With Radical Prostatectomy: A Prospective Cohort Study".
    Urology. 2025 Oct 16:S0090-4295(25)01008-8. doi: 10.1016/j.urology.2025.
    PubMed        
    
    
22. GILLIS CJ
    Editorial Comment on "Patient-Centered Priorities in Prostate Cancer Survivorship Care".
    Urology. 2025 Oct 15:S0090-4295(25)01003-9. doi: 10.1016/j.urology.2025.
    PubMed        
    
    
23. SORENSEN KH, Levinsen AKG, Kjaer TK, Borre M, et al
    Associations between stress urinary incontinence and self-reported functioning and urinary symptoms among survivors of prostate cancer treated with radical prostatectomy.
    Urology. 2025 Oct 15:S0090-4295(25)01011-8. doi: 10.1016/j.urology.2025.
    PubMed         Abstract available
    
    
24. PICCOLINI A, Qian Z, Korn SM, Dagnino F, et al
    Exploring the Impact of Mental Health on PSA Screening: Insights From a Population-Based Survey.
    Urology. 2025;204:112-120.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.